[Newsletter] Vol 71. January 2026
This is Vol.71 Newsletter for January 2026. This issue covers the global pharmaceutical market’s shift toward metabolic diseases from 2026 and the post-GLP-1 competitive landscape, intensifying US–China competition driven by China’s surge in new drug approvals, rapid growth of Korea’s…